# FUS

Source: https://onco.cc/targets/fus/  
OnCo record `fus` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FUS (RNA-binding protein FUS) is a gene. The public catalogues list it as a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Sarcomas, Hepatocellular carcinoma and Liposarcoma.

## Summary

DNA/RNA-binding protein that plays a role in various cellular processes such as transcription regulation, RNA splicing, RNA transport, DNA repair and damage response. Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3'. Binds to nascent pre-mRNAs and acts as a molecular mediator between RNA polymerase II and U1 small nuclear ribonucleoprotein thereby coupling transcription and splicing.

Open Targets scores its association with cancer at 0.64 (direct and indirect evidence; datatypes literature 0.94, animal model 0.38, genetic association 0.00, somatic mutation 0.82). IntOGen calls it a driver in 1 cohort (0 activating, 0 loss-of-function), covering Hepatocellular Carcinoma.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: FUS RNA binding protein; RNA-binding protein FUS; FUS1; hnRNP-P2; HNRNPP2; ALS6
- Tags: cancer-genes-wave
- Symbol: FUS
- Class: other
- Biology: DNA/RNA-binding protein that plays a role in various cellular processes such as transcription regulation, RNA splicing, RNA transport, DNA repair and damage response. Binds to ssRNA containing the consensus sequence 5'-AGGUAA-3'. Binds to nascent pre-mRNAs and acts as a molecular mediator between RNA polymerase II and U1 small nuclear ribonucleoprotein thereby coupling transcription and splicing. Also binds its own pre-mRNA and autoregulates its expression; this autoregulation mechanism is mediated by non-sense-mediated decay. Plays a role in DNA repair mechanisms by promoting D-loop formation and homologous recombination during DNA double-strand break repair. In neuronal cells, plays crucial roles in dendritic spine formation and stability, RNA transport, mRNA stability and synaptic homeostasis. Location: Nucleus (UniProt). Locus 16p11.2 (HGNC).
- Where found: Sarcomas: Open Targets association 0.61 with sarcoma (MONDO_0005089); Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC); Liposarcoma: Open Targets association 0.56 with liposarcoma (MONDO_0005060)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:4010: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:4010
- UniProt P35637: https://www.uniprot.org/uniprotkb/P35637/entry
- NCBI Gene 2521: https://www.ncbi.nlm.nih.gov/gene/2521
- Ensembl ENSG00000089280: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000089280

## Connected records

- collections: [IntOGen](https://onco.cc/collections/intogen/), [Open Targets Platform](https://onco.cc/collections/open-targets/)
- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Liposarcoma](https://onco.cc/cancers/liposarcoma/), [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- pathways: [The blood-brain barrier & brain metastasis](https://onco.cc/pathways/blood-brain-barrier-metastasis/)
- trials: [A Prospective Pivotal Study to Evaluate the Efficacy and Safety of Avastin® Bevacizumab (BEV) With or Without Microbubble-mediated Focused Ultrasound (FUS-MB) Using NaviFUS System in Recurrent Glioblastoma Multiforme Patients](https://onco.cc/trials/nct06496971/)

---
JSON: https://onco.cc/api/v1/entities/fus.json